Compile Data Set for Download or QSAR
Report error Found 564 Enz. Inhib. hit(s) with all data for entry = 10313
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM526972(US11186582, Example 1)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM50236235(CHEMBL4066029 | US11186582, Example 4)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM50236236(CHEMBL4095099 | US11186582, Example 5)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM50236228(CHEMBL4076035 | US11186582, Example 6)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent
PDB3D3D Structure (crystal)
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM526977(US11186582, Example 9)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM526978(US11186582, Example 83)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM526979(US11186582, Example 109)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM526980(US11186582, Example 120)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM526981(US11186582, Example 134)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM526982(US11186582, Example 139)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM526983(US11186582, Example 141)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM526984(US11186582, Example 150)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM526985(US11186582, Example 174)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM526986(US11186582, Example 178)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM526987(US11186582, Example 179)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM526988(US11186582, Example 182)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM526989(US11186582, Example 184)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM526990(US11186582, Example 186)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM526991(US11186582, Example 190)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM526992(US11186582, Example 195)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM526993(US11186582, Example 196)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM526994(US11186582, Example 197)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM526995(US11186582, Example 193 | US11186582, Example 200)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM526996(US11186582, Example 207)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM526997(US11186582, Example 208)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM526998(US11186582, Example 209)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM526999(US11186582, Example 210)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM527000(US11186582, Example 211)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM50236271(CHEMBL4103411 | US11186582, Example 225)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM527002(US11186582, Example 232)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM527003(US11186582, Example 233)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM527004(US11186582, Example 234)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM50236275(CHEMBL4081851 | US11186582, Example 235)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM50236276(CHEMBL4082820 | US11186582, Example 239)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM527007(US11186582, Example 242)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM527008(US11186582, Example 253)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM527009(US11186582, Example 254)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM527010(US11186582, Example 257)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM527011(US11186582, Example 258)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM527012(US11186582, Example 259)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM527013(US11186582, Example 262)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM527014(US11186582, Example 263)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM50236244(CHEMBL4065588 | US11186582, Example 268)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM50236225(CHEMBL4074744 | US11186582, Example 269 | US114198...)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent
PDB3D3D Structure (crystal)
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM527017(US11186582, Example 270)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM527018(US11186582, Example 271)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM527019(US11186582, Example 273)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM527020(US11186582, Example 274)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM527021(US11186582, Example 275)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM527022(US11186582, Example 276)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

Displayed 1 to 50 (of 564 total ) | Next | Last >>
Jump to: